OMER Latest Headlines

Omeros’ OncotoX-AML Shows Up to 99% Reduction in Leukemia-Linked Cells—Will This Change AML Treatment?

Market Chameleon (Tue, 17-Feb 9:30 AM)

Omeros Reschedules YARTEMLEA FDA Approval Call—Landmark Therapy Preps for January 2026 U.S. Launch

Market Chameleon (Mon, 29-Dec 7:06 AM)

OMER Call Spread Buyers Net 26.4% in a Day as FDA Approval Sparks Bullish Surge

Market Chameleon (Wed, 24-Dec 11:35 AM)

FDA Approval of Omeros' YARTEMLEA Sets New Benchmark for TA-TMA Treatment—Robust Response and Survival Data Highlight Potential

Market Chameleon (Wed, 24-Dec 11:07 AM)

FDA Approval of Omeros’ YARTEMLEA Establishes New Standard of Care for TA-TMA

Market Chameleon (Wed, 24-Dec 9:16 AM)